MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is developing an artificial intelligence platform that uses voice analysis to detect drug and alcohol impairment, potentially transforming a testing market projected to grow from $2.5 billion in 2025 to $4.2 billion by 2033. The technology estimates intoxication levels by analyzing more than 140 acoustic markers from short voice samples, trained on over 50 million data points.
According to the company, the system offers a non-invasive alternative to traditional breathalyzers, saliva tests, and laboratory analysis, which are often time-consuming and costly. The global drug and alcohol testing devices market expansion reflects rising safety requirements and stricter regulatory oversight across industries.
MindBio’s initial commercial focus is on the mining sector, particularly in South America, where large workforces and high-risk operating environments create demand for rapid impairment screening. Other potential applications include aviation, construction, call centers, law enforcement, and mental health settings, where high-volume screening is currently expensive and logistically challenging.
“The market for workplace drug and alcohol detection is expanding as employers face increasing pressure to improve safety while reducing the cost and friction of traditional testing methods,” the company stated. This creates an opportunity to modernize a process that remains heavily dependent on breathalyzers, urine testing, and lab work.
MindBio’s voice analysis technology could address these pain points by enabling quick, remote, and frequent testing without the need for specialized equipment or trained personnel. The company has spent several years developing the platform and is now positioning it for commercial deployment.
For more information about MindBio Therapeutics, visit the company’s newsroom at https://ibn.fm/MBQIF.
